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Abstract
The synthesis and crystal structures of bis(S-methylisothiouronium) (MSTUH)+, N,N’-bis((3-
4+ Z+ guanidinopropyl)piperazinium (PipeC3GuaH4) and hexamidinium (HexaH2) tetrachloro
platinate(ll) salts called hereafter PtMSTU, PtPipeC3Gua and PtHexa respectively were
investigated. These compounds contain the "amidine" function C(=NH)NH2 in which the H
atoms supplied by the acid have become attached to the imino group of each terminal amidino
function. Moreover, in PtPipeC3Gua, the nitrogen atoms of the chair-piperazine moiety are also
protonated. The influence of tetrachloroplatinate(ll) counteranion versus sulfate, nitrate and
diisethionate in the in vivo nitrite inhibition by the (MSTUH)+, (PipeC3GuaH4)
4+ and (HexaH2)
2+
cations was investigated. The three tetrachloroplatinate(ll) salts, unexpectedly, do not inhibit
significantly the in vivo nitrite production in comparison with the other salts sulfate, nitrate and
diisethionate and their corresponding previous countercations which exhibit NO synthase
inhibition, especially bis(S-methylisothiouronium) sulfate, a selective and potent inducible NO
synthase iNOS inhibitor commonly used as standard.
1. Introduction
The free radical and paramagnetic molecule nitdc oxide (NO) is produced enzymatically in
physiological and pathological conditions by a family of NO synthases NOS which catalyze the
oxidation of L-arginine from the guanidino group to L-citrulline. These enzymes include
constitutive cNOS and inducible iNOS forms. NO from endothelial constitutive isoform
(ecNOS) is a potent vasodilator and was identified with the endothelium dependent relaxing
factor EDRF which mediates vascular relaxation in response to acetylcholine and substance P
]. NO is also implicated in the regulation of blood pressure and inhibits platelet aggregation
and leukocyte adhesion 2 ]. Endothelial overproduction of NO is implicated in atherosclerosis,
diabetes and hypertension 3 ]. The continuous release of NO from the ecNOS keeps the
vasculature in a continuous state of active vasodilatation.
The neuronal enzyme is found in brain and in peripheral nervous cells. In addition to its role in
blood vessels, NO is a neurotransmitter found in high density in emotion-regulating brain regions
[4 ]. NO from the constitutive neuronal isoform is implicated in neurodegeneration and
neuroinjury. The inducible form iNOS is expressed in response to immunological stimuli in
macrophages and other cells smooth muscle cells, hepatocytes and produces large amounts of
NO which can act as cytotoxic molecule 5 ]. The cytotoxicity of NO from activated macrophages
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plays a role in their antimicrobial activity. NO synthesized by lymphocytes is greatly implicated in
apoptosis phenomena. Recent studies showed that treatment with exogenous NO produces DNA
strand breaks 6 ]. The generation of endogenous NO in large amount is implicated in circulatory
shock secondary to the release of the pr0iflammatory cytokines tumor necrosis factor TNFx and
interleukine ILl 7 ]. Antiinflammatory cytokines including IL4, ILl0 and IL13 inhibit the
induction of iNOS. Overproduction of NO by iNOS has been implicated in the chronic
inflammation, vascular dysfunction in diabetes and transplant rejection. Novel therapeutic
approaches could be designed to modulate the NO biosynthesis drugs with high selectivity for
iNOS inhibition may be useful for treatment of neurodegenerative disorders, chronic inflammatory
diseases and septic shock whereas drugs inhibiting brain NO synthase bNOS may be protective
against neuroinjury.
Many types of NOS inhibitors are known. The generation of NO can be inhibited by
analogues of the substrate L-arginine No-propyI-L-arginine was recently described as a potent
and neuronal nitric oxide synthase inhibitor 8 ]. Other classes of compounds that are not amino
acids but containing the amidine function C = (NH) NH2 ), such as amidines 9 ], S-
alkylisothioureas 10 and substituted aminoguanidines and aminoisothioureas 11 ], are reported
to be inhibitors of NOS. Bis(S-methylisothiouronium) sulfate is known to be a potent and
preferential inhibitor of human and rat iNOS ;it exerts beneficial effects and improves survival in a
rodent model of septic shock[ 12 ]. More recently, 1H-pyraz01e-l-carboxamidine hydrochloride
(or PCA and its substituted derivatives have been shown to inhibit NOS with an increased
selectivity toward iNOS when the pyrazole ring is substituted, as in 4-methyI-PCA 13 ].
In the course of our investigations, we have previously examined the ability of some N,N’-
(alkane-l,0-diyl)bis(guanidinium) and N,N’-bis(3-guanidinopropylpiperazine) dinitrates to inhibit
nitrite production in rat pleural cavity 14 ]. Moreover, in a previous paper, we have demonstrated
that N,N’-(octane-l,8-diyl)bis(guanidinium) tetrachloroplatinate(ll) exhibits cytostatic effects
against trophozoites of an Acanthamoeba strain, in contrast to the tetrachloropalladate(ll) salt
which lacks this effect 15 ].
This prompted us to study the possible modifications of pharmacological properties of NOS
inhibitors when pharmacologically inert anions sulfate, nitrate, chloride were replaced by other
counteranions such as tetrachloroplatinate(ll) which might reverse or enhance the expected
properties.
Hexamidine diisethionate is a drug well-known for its antimicrobial effects which result from
cationic surface active properties as a consequence of the bipolar structure of its cation. To our
knowledge, its NOS inhibitor properties have not been described.
The aim of this work was to compare the anti-NO synthase properties of bis(S-
methylisothiouronium) sulfate, a compound chosen as a reference NO inhibiting drug in our
previous experiments ), N,N’-bis(3-guanidinopropylpiperazine) dinitrate and hexamidine
diisethionate versus the corresponding tetrachloroplatinate(ll) salts, called hereafter PtMSTU,
PtPipeC3Gua and PtHexa respectively. All these compounds contain the amidine function.
2. Results and discussion.
2.1. Descriptions of the structures.
In the three tetrachloroplatinate(ll) salts, the amidine function C(=NH)NH2 was
protonated with the H atoms supplied by the acid at the imino group of each terminal amidino
function. (Tables 1 and 2
2.1.1. Description ofthe PtMSTU structure. Figure la
The asymmetric unit consists of half of a square planar [PtCI] anion and one [MSTUH]
cation. The S(1) C(2) bond length of 1.782(7) A is in good agreement with the length of a pure $
C single bond 1.82 A while the S(1) C(1) bond length (1.730(6) A is significantly shorter
and indicates arl approximately 50% double-bond character. The atoms $(1), C(1), N(1) and N(2)
of the isothiouronium cation were coplanar and the methyl carbon. C(2) is 0.17 A out of this plane,
to which the S(1) C(2) bond is inclined at an angle of 5.6". Between the two N C $ bond
angles, there is a difference of 7.6". The larger angle is the one to which the remote substituent
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on the sulfur atom stands in a syn-relationship as shown by the torsion angles of 6.02 for the N(2)
C(1) S(1) C(2) and of-174.48 for the N(1)- C(1) S(1) C(2). Similar observations have
been made on the crystal structures of bis(S-methylisothiouronium) sulfate 16 and S-
methylthiouronium p-chlorobenzoate 17 ].
All the amidinium H atoms are involved in hydrogen bonding to C1(1), C1(1), C1(2) and
C1(2"). The most noticeable feature is that there is one bifurcated hydrogen bond involving H(102)
attached to N(1) with C1(1 ) and C1(2) symmetry code i’- x, y, z ii" x, y, z
iii :x, l+y,z).
Cl2
CI1 CI2
H202
2 CI1
H101
C1
H
CI2
Ptl
CI1
Figure a Molecular structure of bis(S-methylisothiouronium) tetrachloroplatinate(ll), showing the
atom numbering scheme.
2.1.2. Description of the PtPipeC3Gua structure. Figure b
The asymmetric unit consists of two half crystallographically independent and square planar
[PtCI4]
2 anions and one half [PipeC3GuaH4]
4* cation where PipeC3GuaH4 is the tetraprotonated
form of the organic ligand N,N’-bis(3-guanidinopropyl)piperazine. The crystal structure shows that
i) the organic cation presents a center of symmetry, ii) the four H atoms supplied by the acid have
become attached to the two nitrogen atoms of the piperazine moiety and, to the imino group of
each terminal amidino function. The three equivalent guanidinium C N bonds vary from 1.31(1)
to 1.34(2) ,& which are in agreement with those found in N,N’-(octane-l,8-diyl)bis(guanidinium)
tetrachloroplatinate(ll), the so-called [OBG]2*[PtCI4]2 from 1.295(9) to 1.314(8) ,& 15 ]. The
atoms C(11), N(12), N(13) and N(14) are coplanar and the propyl carbon C(10)is 0.14 ,& out of this
plane, to which the N(14) C(10) is inclined at an angle of 5.40. The diprotonated piperazinium
moiety exhibits a chair conformation, with the N(1) and its centrosymmetrically related atom being
0.70 A out of the C(2) C(3) C(2=) C(3=) equatorial plane symmetry code :i 2 x, y,
z ). The torsion angles in the N(14) C(10) C(20)- C(30) N(1) sequence are in the range of 65.2
to -173.4
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The crystal packing is characterized by four intermolecular bonds involving hy.d.rogen atoms
attached to N(12), N(13) and N(14) from the guanidinium moiety with C1(2), C1(3"), CI(S’) and
C1(4) and another one from the hydrogen atom attached to the piperidinium N(1) atom with C1(1 ’)
symmetry code ii 1-x,-y,-z iiix,-y+ 1/2, z-1/2).
C2
CI3 iii N C3
"J c,o "’.... ""
N12 c__ ( Cll
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Figure lb Molecular structure of N,N’-bis(3-guanidinopropyl)piperazinium tetrachloroplatinate(ll).
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Figure lc Molecular structure of hexamidinium tetrachloroplatinate(ll).
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Figure 2 Nitrite production m 4- S.E.M. )in the rat pleural cavity 0.5 hour A and 7 hours B
after injection of 0.1 mL of carrageenan 10 g/L with or without C controls simultaneous
addition of MSTU S-methylisothiouronium sulfate ), PipeC3Gua (N, N’-bis(3-
guanidinopropyl)pi perazine dinitrate), Hexa (hexamidine diisethionate) and their
tetrachloroplatinate(ll) salts + Pt at the same dose of 5x10
5 M. Number of animals included in
each group:5-8;**p < 0.01
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2.1.3. Description ofthe PtHexa structure. Figure lc
The two phenyl dngs of the hexamidinium are twisted by 14.4" with respect to each other,
compared to 35* in the pentamidine complex formed with the dodecanucleotide
d( CGCGAATTCGCG )2 18 ]. The torsion angles show that the central -(CH2)6-linker chain
exhibits an all trans configuration, as in free pentamidine 19 ], in contrast with the pentamidine-
dodecanucleotide complex in which the deviations from 180" pure staggered values are
responsible for the shortening of the chain length to 9.13 . compared to 9.75 A value found in the
crystal structure of free pentamidine 19] ). The amidinium groups are twisted out of the planes of
the phenyl dngs by 25.0 and 155.0" compared to 27* in free pentamidine and to 3 and -6* in the
pentamidine complex. Moreover, in PtHexa, the dihedral angle between the two amidinium
groups is 132.5".
The crystal packing is characterized by intermolecular bgnds invol.v.ing C1(2) via hydrogen
H(12) attached to N(1), CI(3) via H(22) attached to N(2), CI(1 and CI(4) via the two hydrogen
atoms attached to N(21) and finally O(104") from the dimethylformamide via H(221) attached to
N(22)(symmetrycode i:2+x,l+y,z;ii:-x,l-y,l-z;iii:-l+x, y,z)
2.2. Anti NO synthase properties.
NO generation was assessed 0.5 and 7 hours after the induction of the inflammatory
reaction. According to previous studies 20 this production correlated to the activation of
constitutive and inducible NO synthases respectively.
The three non-platinum salts tested demonstrated a significant inhibition of NO generation
during an experimental inflammatory reaction. This inhibition was observed on constitutive NOS
(in the early time of inflammation and on inducible NOS in the later time and may be
beneficial in some pathological situations[ 21 ]. Moreover, the NO synthase antiinhibitor
properties of these new tetrachloroplatinate(ll) salts is described here for the first time, to our
knowledge. These tetrachloroplatinate(ll) salts did not, however, enhance nitrite production as
shown in Figure 2 A and Figure 2 B. As NO exerts an ambivalent role on many physiological
functions, control of its over-production may be of therapeutic value 22 ]. This property,
demonstrated for an antiseptic compound such as hexamidine, may add some cytotoxic activity to
its other properties. On the contrary, if this anti-NO property is unsuitable, formation of
tetrachloroplatinate(ll) salts deprived of action on NOS may be appropriate.
3. Experimental
Synthesis ofthe tetrachloroplatinate(ll) salts.
K2PtCI4 Jansen Chimica was used as received.
3.1.1. Synthesis of bis(S-methylisothiouronium) tetrachloroplatinate(ll).
Bis(S-methylisothiouronium) sulfate ((MSTUH)2SO4) Aldrich [0.556 g; 2 mmol] was
dissolved in 1 M HCI 20 mL and a solution of K2PtCI 0.415 g;1 mmol in 1 M HCI 5 mL
was added. The reaction mixture was heated and rotary evaporated to dryness. The crystalline
red-brown solid was dissolved in M HCI and recrystallized at room temperature. Crystals were
washed with methanol 4 x 10 mL and dried at 90* C for 2 h to give 0.386g (75 % of
[MSTUH]2[PtCI].
3.1.2. Synthesis of N,N’-bis(3-guanidinopropyl)piperazinium tetrachloroplatinate(ll)
N,N’-bis(3-guanidinopropyl)piperazine (pipeC3Gua) dinitrate was synthesized as previously
described 14 ]. This compound 0.410 g; mmol was dissolved in M HCI 20 mL) by heating
at 50"C and stirring. To this solution was added K2PtCI 0.415 g; 1 mmol dissolved in M HCI
5 mL ). The peach-coloured tetrachloroplatinate salt of PipeC3GuaH4 precipitated rapidly. The
powder was filtered off and washed several times with water, ethanol, diethylether and dded at
90"C for 24 h. Yield 0.530 mg 85%
132Georges Morgant, Bernard Viossat et al. Metal-Based Drugs
3.1.3. Synthesis of hexamidinium tetrachloroplatinate(ll)
Hexamidine diisethionate 0.607g mmol was dissolved in 1 M HCI 100 mL by
heating at 70C for 0.5 h and a solution of K2PtCI4 0.415 g mmol in 1 M HCI 5 mL was
added. A flesh-coloured precipitate was obtained immediately, filtered and washed several times
with water, ethanol and diethylether then dried at 90C for 24 h. Crystals suitable for X-ray
crystallography were obtained by recrystallization of the salt from hot DMF.
Table
Crystal Data
compound
formula
fw(g)
shape
colour
size, mm
crystal system
space group
a,,
b,A
c,A
/,
v,A
Z
F(000)
p (calcd), g.cm"3
(MoKo), cm-
Data collection
20 range, deg
range of h
range of k
range of
Absorption correction
T min/T max
no. of rflns collected
no. of unique rflns
reflections used,
Refinement
R / Rw
Weighting Scheme
Coefficient .At
GOF
(/)m,x
APmn/Apmax e., 3
Number of parameters
PtMSTU PtPipeC3Gua PtHexa
2[C2N2H7S]
+ [PtCI4]
2" [C12H32Ns]4+2[PTCI4]
2" [C20H28N40212+[PtCI4]
2"
C3H7NO
519.2 962.24 766.47
parallelepiped parallelepiped parallelepiped
red-brown peach flesh
0.450, 0.400, 0.200 0.400, 0.180, 0.120 0.625, 0.500, 0.300
triclinic monoclinic triclinic
P-1 P 21/c P-1
6.350(2) 11.694(2) 9.060(3)
7.278(3) 9.497(3) 12.787(5)
8.642(3) 11.758(4) 13.55(2)
72.48(2) 90.0 107.156(7)
72.68(2) 92.55(2) 99.553(6)
81.10(3) 90.0 96.94(3)
362.7(2) 1304.6(7) 1455.0(3)
2 2
242.35 896.54 752.35
2.38 2.45 1.75
107.73 116.72 52.74
4.0 < 2e < 48 0 < 2e < 56 4.0 < 2e < 48
0-+8 0-+ 15 0-+ 12
-9 -+ 9 0 -+ 12 -17 -+ 17
-10-+11 -15 -+ 15 -19 -+ 18
DIFABS DIFABS DIFABS
0.95 / 1.00 0.94 / 1.00 0.99 / 1.00
1747 3479 8939
1747 3479 8939
1730(1> 3((I)) 1378(1> 3((I)) 6499(1>3((I))
0.033 /0.037 0.059 / 0.062 0.036 / 0.044
Chebyshev Chebyshev Chebyshev
12.1,-9.85, 8.31 1.92,-0.259, 1.50 8.75,-2.79, 6.93
1.05 1.11 1.57
0.016 0.015 0.0006
-1.19 / 1.02 -2.47 / 1.71 -1.17 / 2.08
71 229 356
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3.2. Structure determination.
The refined cell constants and other relevant crystal data are presented in Table 1, together
with details of the intensity measurements. The crystals were mounted, using glass fibers, on an
ENRAF-NONIUS CAD4 diffractometer equipped with a graphite monochromator. The lattice
parameters were refined using 25 reflections. The data were collected using the 0-2e scan
technique and with Mo Ko radiation % = 0.71073 ,& ).
During the data collection, three intensity control reflections were monitored every two
hours, showing no loss of intensity. The data were corrected for Lorentz and polarisation effects.
The structure was solved by a combination of direct methods using SIR procedure 23 and
heavy-atom techniques and refined by full-matrix least-squares method based on F, using
CRYSTALS 24 ]. An empirical absorption correction with the program DIFABS 25 was used.
Anisotropic displacement parameters were assigned to all non-H atoms. The hydrogen atoms were
introduced in calculated idealized positions (d(C-H) 0.98 ,& and their atomic coordinates were
recalculated after each cycle. They were given isotropic thermal parameters 20% higher than
those of the carbon to which they are attached. Least-squares refinements were performed by
minimizing the function .w(IFol-lFol)=, where Fo and Fc are the observed and calculated structure
factors. The weighting scheme used in the last refinement cycles was w w’[1-(AF/6(Fo)2]
2
where w’ l/ZlnArTr(x) with 3 coefficients Ar for the Chebyshev polynomial ArTr(x) where x was
Fc/F(max) 26 ]. Models reached convergence with R %(IIFoI-IFolI)/(IFol) and Rw ,w(IFol-
IFel)2/T_,w(Fo)2 ]1/2, having values listed in Table 1. Criteria for a satisfactory complete analysis were
ratios of rms shift to standard deviation less than 0.1 and no significant features in final difference
maps. Details of data collection and refinement are given in Table 1. Calculations were
performed with a PC CRYSTALS package program. The drawings of the molecules were
generated using CAMERON 27 ]. The atomic scattering factors were taken from International
Tables for X-ray Crystallography 28 ].
3.3. Biological assays.
3.3.1. Material.
Carrageenan X was obtained from Pierrefitte Auby Neuilly/Seine, France ). Hanks’
solution without phenol red ), N-(1-naphthyl)ethylenediamine, and sulfanilamide were purchased
from Sigma Chemical Co. St. Louis, Mo, USA ). Phosphoric acid was purchased from Merck
(Darmstadt, Germany and bis(S-methylisothiouronium)sulfate was purchased from Aldrich
Steinheim, Germany ).
3.3.2. Animals and treatments
Male Sprague-Dawley rats weighing 180-200 g Depre, Saint-Doulchard, France were
used for all experiments 29 ]. Protocols were submitted to and approved by the local ethics
committee.
Pleurisy was induced by intrapleural injection of 0.1 mL of 10 g/L carrageenan X suspension
in saline 30 ].
Bis(S-methylisothiouronium) sulfate, PipeC3Gua dinitrate and hexamidinium diisethionate
on the one hand and the corresponding tetrachloroplatinate(ll) salts on the other hand were
administered 0.1 mL with the inflammatory 14 ]. Animals were euthanized with ether, and the
right pleural cavity was opened for pleural exudate collection after 30 minutes or seven hours.
Samples were centrifuged at 500 g for 5 min, and the supernatants were then centrifuged at 1000
g for 20 min in order to remove exudate fibrin. Samples were then adjusted to a final volume of
ml with Hank’s solution and stored at 80C until nitrite determination was carded out.
3.3.3. Nitrite determination in pleural exudate.
Nitrite was measured in pleural exudate as a parameter of NO formation 31 ]. Aliquots of
0.1 mL were incubated in individual wells of a 96-well plate, with 0.1 mL of Griess reagent 0.5 g/L
N-(1-naphthyl)ethylenediamine and 5 g/L sulfanilamide in phosphoric acid 50 g/L )), at room
temperature for 10 min. The absorbance was measured at 550 nm using a microplate reader
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(Dynatech, MRX ), in comparison with the incubating medium Hank’s solution without cells.
Sodium nitrite was used to establish a nitrite standard curve.
3.3.4. Statistical analysis
The Mann-Whitney U test in the computer program Statview II was carded out in each
group between treated and non treated rats. Results were given as a mean + S.E.M. Differences
with p < 0.05 were considered as significant.
Table 2 Interatomic distances and bond angles (/k, deg.). E.s.d’s in parentheses refer to the last
significant digit.
PtMSTU
PT(1) CL(1) 2.297(1) CL(2) PT(1) CL(1) 90.01(5)
PT(1)- CL(2) 2.305(1) N(1) C(1) N(2) 121.6(6)
N(1) C(1) 1.311(8) N(1) C(1) S(1) 115.4(5)
C(1) N(2) 1.302(8) N(2) C(1) S(1) 123.0(5)
C(1) S(1) 1.730(6) C(1) S(1) C(2) 103.8(3)
S(1) C(2) 1.782(7)
PtPipeC3Gua
PT(1) CL(1)
PT(1)- CL(2)
2.297(3) CL(1 PT(1 CL(2) 91.1 (1)
2.298(3) CL(3) PT(2) CL(4) 91.2(1)
PT(2) CL(3)
PT(2) CL(4)
2.299(3) C(2) N(1) C(3) 109.2(8)
2.290(4) C(2) N(1) C(30) 110.0(8)
C(3) N(1) C(30) 113.1(8)
1.52(1) C(10) N(14) C(11.) 126.6(11)
1.50(1) N(1) C(2) C(3.’) 110.5(9)
1.51(1) N(1) C(3) C(2’) 110.8(10)
1.34(2) N(14) C(10) C(20) 111.8(9)
1.31(1) N(12)- C(11) N(13) 118.9(13)
1.46(1) N(12) C(11) N(14) 121.5(12)
1.33(2) N(13) C(11) N(14) 119.7(12)
1.48(2) C(10)- C(20) C(30) 111.8(9)
1.51(1) N(1) C(30)- C(20) 114.1(9)
1.48(1)
N(1) -C(2)
N(1) C(3)
N(1) C(30)
N(12) C(11)
N(13) C(11)
N(14)- C(10)
N(14) C(1.1)
C(2) C(3’)
C(10) C(20)
C(20)- C(30)
symmetry code :i 2- x, y, z
PtHexa
PT(1) CL(1)
PT(1) CL(2)
PT(1 CL(3)
PT(1)- CL(4)
2.310(1) C(2) C(3) 1.389(6)
2.300(1) C(2) C(7) 1.393(6)
2.318(1) C(3) C(4) 1.388(7)
2.297(1) C(4) C(5) 1.390(7)
C(5) C(6) 1.398(6)
1.357(5) C(6) C(7) 1.374(6)
1.448(6) C(8) C(9) 1.499(7)
1.351(5) C(9) C(10) 1.523(7)
1.424(6) C(10) C(30) 1.522(7)
1.234(6) C(21) C(22) 1.472(6)
1.304(6) C(22) C(23) 1.390(6)
1.310(6) C(22) C(27) 1.391(6)
1.314(6) C(23) C(24) 1.381(6)
1.307(6) C(24) C(25) 1.388(6)
1.465(7) C(25) C(26) 1.397(7)
1.446(7) C(26) C(27) 1.376(6)
1.316(7) C(28)- C(29) 1.498(7)
0(1) c(5)
0() c(8)
O(21) C(25)
O(21) C(28)
O(104)- C(102)
N() -C()
N(2) -C(1)
N(21) C(21)
N(22) C(21)
N(103)- C(100)
N(103)- C(101)
N(103)- C(102)
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C(1) C(2) 1.471(6) C(29)- C(30) 1.525(7)
CL(2) PT(1) CL(1)
CL(3) PT(1) CL(1)
CL(4 )- PT(1) CL(1)
CL(2) PT(1) CL(3)
CL(2) PT(1) CL(4)
CL(3) PT(1) CL(4)
C(5) O(’) C(8)
C(25) O(21) C(28)
89.58(4)
178.97(4)
90.34(5)
91.16(4)
177.97(5)
88.95(4)
117.6(4)
117.8(4)
C(100)- N(103)- C(101) 118.1(5)
C(100)- N(103)- C(102) 120.6(5)
C(101)- N(103)- C(102) 121.3(5)
N(1) C(1) N(2) 120.0(4)
N(1) C(1) C(2) 119.4(4)
N(2) C(1) C(2) 120.7(4)
C(1) C(2) C(3) 119.0(4)
C(1) C(2) C(7) 121.8(4)
C(3) C(2) C(7) 119.2(4)
C(2) C(3) C(4) 120.8(4)
C(3) C(4) C(5) 119.4(4)
O(1) C(5) C(4) 123.9(4)
O(1) C(5) C(6) 116.1(4)
C(4) C(5) C(6) 120.0(4)
C(5) C(6) C(7) 119.9(4)
C(2) C(7) C(6) 120.7(4)
O(1) C(8) C(9) 107.1(4)
C(8) C(9) C(’0) ’.6(5)
C(9) C(10) C(30) 112.1(5)
N(21)- C(21)- N(22) 120.1(4)
N(21) C(21)- C(22) 120.1(4)
N(22) C(21) C(22) 119.8(4)
C(21) C(22) C(23) 121.1(4)
C(21)- C(22)- C(27) 120.3(4)
C(23) C(22) C(27) 118.6(4)
C(22) C(23)- C(24) 120.6(4)
C(23) C(24) C(25) 120.3(4)
O(21) C(25)- C(24) 116.5(4)
O(21) C(25)- C(26) 124.1(4)
C(24) C(25) C(26) 119.4(4)
C(25) C(26)- C(27) 119.7(4)
C(22) C(27) C(26) 121.2(4)
O(21) C(28)- C(29) 109.9(4)
C(28)- C(29)- C(30) 109.6(5)
C(10)- C(30)- C(29) 115.0(5)
Other crystallographic details, comprising fractional atomic coordinates, hydrogen bonds,
thermal parameters, and tables of observed and calculated structure factors are available on
request.
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